Evaluation of Diffusion-Weighted MR Imaging at Inclusion in an Active Surveillance Protocol for Low-Risk Prostate Cancer

被引:61
|
作者
Somford, Diederik M. [1 ,2 ]
Hoeks, Caroline M. [3 ]
Hulsbergen-van de Kaa, Christina A. [4 ]
Hambrock, Thomas [3 ]
Futterer, Jurgen J. [3 ]
Witjes, J. Alfred [2 ]
Bangma, Chris H. [5 ]
Vergunst, Henk [1 ]
Smits, Geert A. [6 ]
Oddens, Jorg R. [7 ]
van Oort, Inge M. [2 ]
Barentsz, Jelle O. [3 ]
机构
[1] Canisius Wilhelmina Hosp, Dept Urol, NL-6532 SZ Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Urol, NL-6525 ED Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Dept Radiol, NL-6525 ED Nijmegen, Netherlands
[4] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NL-6525 ED Nijmegen, Netherlands
[5] Erasmus MC, Dept Urol, Rotterdam, Netherlands
[6] Rijnstate Hosp, Dept Urol, Arnhem, Netherlands
[7] Jeroen Bosch Hosp, Dept Urol, sHertogenbosch, Netherlands
关键词
prostatic neoplasms; magnetic resonance imaging; diffusion magnetic resonance imaging; active surveillance; apparent diffusion coefficient; RADICAL-PROSTATECTOMY; GLEASON SCORE; GUIDED BIOPSIES; PATHOLOGICAL FEATURES; HISTOLOGIC GRADE; REPEAT BIOPSY; AGGRESSIVENESS; COEFFICIENT; TUMOR; MEN;
D O I
10.1097/RLI.0b013e31827b711e
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: We aimed to determine whether diffusion-weighted magnetic resonance imaging, by means of the apparent diffusion coefficient (ADC), is able to guide magnetic resonance-guided biopsy in patients fit for active surveillance (AS) and identify patients harboring high-grade Gleason components not suitable for AS. Materials and Methods: Our study was approved by the institutional review board of all participating hospitals, and all patients signed informed consent at inclusion. Fifty-four consecutive patients with low-risk prostate cancer (PCa) underwent multiparametric magnetic resonance imaging (MP-MRI) at inclusion for AS. Cancer-suspicious regions (CSRs) upon 3-T MP-MRI were identified in all patients, and magnetic resonance-guided biopsy was performed in all CSRs to obtain histopathological verification. For all CSRs, a median ADC (mADC) was calculated. Wilcoxon signed ranks and Mann-Whitney tests was performed to detect differences between the groups. We used the area under the receiver operating characteristic curve to evaluate the accuracy of mADC to predict the presence of PCa in a CSR. Level of statistical significance was set at P < 0.05. Results: Mean mADC in the CSRs with PCa was 1.04 x 10(-3) mm(2)/s (SD, 0.29), whereas the CSRs with no PCa displayed a mean mADC of 1.26 x 10(-3) mm(2)/s (SD, 0.25; P < 0.001). Cancer-suspicious regions with a high-grade Gleason component displayed a mean mADC of 0.84 x 10(-3) mm(2)/s (SD, 0.35) vs a mean mADC for the low-grade CSRs of 1.09 x 10(-3) mm(2)/s (SD, 0.25; P < 0.05). A diagnostic accuracy of mADC for predicting the presence of PCa in a CSR with an area under the receiver operating characteristic curve of 0.73 was established (95% confidence interval, 0.61-0.84). Conclusions: Median ADC is able to predict the presence and grade of PCa in CSRs identified by MP-MRI.
引用
收藏
页码:152 / 157
页数:6
相关论文
共 50 条
  • [31] Characterization of prostate cancer with MR spectroscopic imaging and diffusion-weighted imaging at 3 Tesla
    Mazaheri, Yousef
    Shukla-Dave, Amita
    Goldman, Debra A.
    Moskowitz, Chaya S.
    Takeda, Toshikazu
    Reuter, Victor E.
    Akin, Oguz
    Hricak, Hedvig
    MAGNETIC RESONANCE IMAGING, 2019, 55 : 93 - 102
  • [32] Variation in the use of active surveillance for low-risk prostate cancer
    Loeppenberg, Bjoern
    Friedlander, David F.
    Krasnova, Anna
    Tam, Andrew
    Leow, Jeffrey J.
    Nguyen, Paul L.
    Barry, Hawa
    Lipsitz, Stuart R.
    Menon, Mani
    Abdollah, Firas
    Sammon, Jesse D.
    Sun, Maxine
    Choueiri, Toni K.
    Kibel, Adam S.
    Quoc-Dien Trinh
    CANCER, 2018, 124 (01) : 55 - 64
  • [33] Active Surveillance for Black Men With Low-Risk Prostate Cancer
    Shen, Xinglei
    Pettaway, Curtis A.
    Chen, Ronald C.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (17): : 1733 - 1734
  • [34] Active Surveillance for Low-Risk Prostate Cancer in Black Patients
    Butler, Santino
    Muralidhar, Vinayak
    Chavez, Janice
    Fullerton, Zoe
    Mahal, Aman
    Nezolosky, Michelle
    Vastola, Marie
    Zhao, Shuang G.
    D'Amico, Anthony V.
    Dess, Robert T.
    Feng, Felix Y.
    King, Martin T.
    Mouw, Kent W.
    Spratt, Daniel E.
    Quoc-Dien Trinh
    Nguyen, Paul L.
    Rebbeck, Timothy R.
    Mahal, Brandon A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (21): : 2070 - 2072
  • [35] THE ERA OF ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER IS HERE
    Sountoulides, Petros
    Obek, Can
    ARCHIVOS ESPANOLES DE UROLOGIA, 2016, 69 (02): : 49 - 51
  • [36] Active Surveillance for Low-risk Prostate Cancer: Will it Become Obsolete?
    Roobol, Monique J.
    EUROPEAN UROLOGY, 2019, 75 (05) : 750 - 751
  • [37] Super active surveillance for low-risk prostate cancer | Opinion: No
    Ghodoussipour, Saum
    Lebastchi, Amir
    Pinto, Peter
    Berger, Andre
    INTERNATIONAL BRAZ J UROL, 2019, 45 (02): : 215 - 219
  • [38] THE QUALITY OF ACTIVE SURVEILLANCE FOR MEN WITH LOW-RISK PROSTATE CANCER
    Levy, Mya E.
    Meyers, Stephanie
    Wood, David P.
    Montie, James E.
    Miller, David C.
    Wei, John T.
    JOURNAL OF UROLOGY, 2009, 181 (04): : 179 - 179
  • [39] Active surveillance beats surgery in low-risk prostate cancer
    Brower, Vicki
    LANCET ONCOLOGY, 2012, 13 (11): : E468 - E468
  • [40] Active Surveillance for Low-risk Prostate Cancer: Developments to Date
    Bangma, Chris H.
    Valdagni, Riccardo
    Carroll, Peter R.
    van Poppel, Hein
    Klotz, Laurence
    Hugosson, Jonas
    EUROPEAN UROLOGY, 2015, 67 (04) : 646 - 648